α1-Antitrypsin deficiency: From genotype to childhood disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 27, Issue 1, 1998, Pages 65-74

  Marcus, Nancy ^a,b   Teckman, Jeffrey H ^a,b   Perlmutter, David H ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM BINDING PROTEIN; CALNEXIN; CHAPERONE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CHILD; ENDOPLASMIC RETICULUM; GENE THERAPY; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; LUNG EMPHYSEMA; LUNG TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTAKE; REVIEW; SMOKING CESSATION; GENETICS; GENOTYPE; LUNG DISEASE;

ALPHA 1-ANTITRYPSIN DEFICIENCY; CHILD; GENOTYPE; HUMANS; LIVER DISEASES; LUNG DISEASES;

EID: 0031595121     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-199807000-00012     Document Type: Review

References (81)

1. 1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976;294:1316-21.
2. 1-antitrypsin deficiency. Hepatology 1995;22:514-7.
3. 1-antitrypsin deficiency in relation to neonatal liver disease. Mol Biol Med 1990;7:161-2.
4. Lobo-Yeo A, Senaldi G, Portmann R, Mowat AP, Mieli-Versani G, Vergani D. Class I and class II major histocompatibility complex antigen expression on hepatocytes: A study in children with liver disease. Hepatology 1990;12:224-32.
5. 1-antitrypsin deficiency. Hepatology 1996;24: 1504-16.
6. 1-antitrypsin: A transgenic mouse model. Science 1988;242: 1404-12.
7. Carlson JA, Rogers BB, Sifers RN, et al. Accumulation of PiZ antitrypsin causes liver damage in transsenic mice. J Clin Invest 1988;83:1183-90.
8. 1-antitrypsin deficiency. N Engl J Med 1980;302:272-6.
9. 1proteinase inhibitor deficiency is expressed in human monocytes and xenopus oocytes injected with human liver mRNA. Proc Natl Acad Sci USA 1985; 82:6918-21.
10. 1-antitrypsin by addition of a second mutation. Science 1988;242:1700-2.
11. McCracken AA, Kruse KB, Brown JL. Molecular basis for defective secretion of variants having altered potential for salt bridge formation between amino acids 240 and 242. Mol Cell Biol 1989; 9:1408-14.
12. 1-antitrypsin variant. J Biol Chem 1989;264:2997-3001.
13. 1-antitrypsin from xenopus oocytes. FEBS Lett 1990;268:21-3.
14. 1-antitrypsin accumulation in the liver. Nature 1992;357:605-7.
15. 1-antitrypsin causes a protein folding defect. Nat Struct Biol 1995; 2:363-7.
16. Bergeron JJM, Brenner MB, Thomas DY, Williams DB. Calnexin: A membrane-bond chaperone of the endoplasmic reticulum. Trends Biochem Sci 1994;19:124-8.
17. Ou W-J, Cameron PH, Thomas DY, Bergeron JJM. Association of folding intermediates of glycoproteins with calnexin during protein maturation. Nature 1993;364:771-6.
18. Sousa MC, Ferrero-Garcia MA, Parodi AJ. Recognition of the oligosaccharide and protein moieties of glycoproteins by the UDP-glucose: Glycoprotein glucosyltransferase. Biochemistry 1992; 310:97-105.
19. Hebert DN, Foellmer B, Helenius A. Glucose trimming and reglucosylation determine glycoprotein association with calnexin in the endoplasmic reticulum. Cell 1995;81:425-53.
20. Rothman JE, Wieland FT. Protein sorting by transport vesicles. Science 1996;272:227-34.
21. Bonifacino JS, Suzuki CK, Lippincott-Schwartz J, Weissman AM, Klausner RD. Pre-Golgi degradation of newly synthesized T-cell antigen receptor chains: Intrinsic sensitivity and the role of subunit assembly. J Cell Biol 1989;109:73-83.
22. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995;83:121-7.
23. Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, Riordan JR. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 1995;83:129-35.
24. Hershko A, Ciechanover A. The ubiquitin system for protein degradation. Annu Rev Biochem 1992;61:761-807.
25. 1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem 1996;271: 22791-5.
26. 1-antitrypsin Z (abstract). Gastroenterology 1998;114: A1353.
27. Werner ED, Brodsky JL, McCracken AA. Proteasome-dependent endoplasmic reticulum-associated protein degradation: An unconventional route to a familiar fate. Proc Natl Acad Sci USA 1996; 93:13797-801.
28. 1-antitrypsin involves release from calnexin and post-translational trimming of asparagine-linked oligosacchandes. J Biol Chem 1997;272:7946-51.
29. Wiertz EJHJ, Tortorella D, Bogyo M, Yu J, Mothes W, Jones TR. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 1996;384: 432-8.
30. McCracken AA, Brodsky JL. Assembly of ER-associated protein degradation in vitro: Dependence of cytosol, calnexin, and ATP. J Cell Biol 1996;131:291-8.
31. Hiller MM, Finger A, Schweiger M, Wolf DH. ER degradation of a misfolded luminal protein by the cytosolic ubiquitin-proteasome pathway. Science 1996;273:1725-8.
32. Plemper RK, Bohmler S, Bordallo J, Sommer T, Wolf DH. Mutant analysis links the translocon and BiP to retrograde protein transport for ER degradation. Nature 1997;388:891-5.
33. Biederer T, Volkwein C, Sommer T. Role of Cue1p in ubiquitination and degradation at the ER surface. Science 1997;278: 1806-9.
34. 1-antitrypsin deficiency. Proc Natl Acad Sci USA 1994;91:9014-8.
35. 1-antitrypsin. J Biol Chem 1997; 272:13446-51.
36. 1-antitrypsin liver disease in a transgenic mouse model. Hepatology 1990;12:40-7.
37. 1 pathological and DNA ploidy studies. Hepatology 1994;19:389-97.
38. Chisari FV, Hepatitis B virus transgenic mice: Insights into the virus and the disease. Hepatology 1995;22:1317-25.
39. Raposo G, van Santen HM, Liejendekker R, Geuze HJ, Ploegh HL. Misfolded major histocompatibility complex class I molecules accumulate in an expanded ER-Golgi intermediate compartment. J Cell Biol 1995;131:1403-19.
40. Dunn WA. Studies on the mechanism of autophagy: Formation of autophagic vacuole. J Cell Biol 1991;110:1923-33.
41. Sidrauski C, Cox S, Walter P. tRNA ligase is required for regulated mRNA splicing in the unfolded protein response. Cell 1996;87: 405-13.
42. Cox JS, Walter P. A novel mechanism for regulating activity of a transcription factor that controls the unfolded protein response. Cell 1996;87:391-104.
43. Sidrauski C, Walter P. The transmembrane kinase Ire1p is a site-specific endonuclease that initiates mRNA splicing in the unfolded protein response. Cell 1997;90:1031-39.
44. Frand AR, Kaiser CA. The ERO1 gene of yeast is required for oxidation of protein dithiols in the endoplasmic reticulum. Mol Cell 1998;1:161-70.
45. Pollard MG, Travers KJ, Weissman JS. Ero1p: A novel and ubiquitous protein with an essential role in oxidative protein folding in the endoplasmic reticulum. Mol Cell 1998;1:171-82.
46. 1-antitrypsin deficiency and liver disease. J Clin Invest 1989;84:1555-61.
47. Pahl HL, Sester M, Gurgert H-G, Baeuerle PA. Activation of transcription factor NF-κB by the adenovirus E3/19K protein requires its ER retention. J Cell Biol 1996;132:511-22.
48. Wilson-Cox D. Alpha-1-antitrypsin deficiency. In: Scriver CB, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease. 6th ed. New York: McGraw-Hill, 1989:2409-37.
49. Schwaiblmair M, Vogelmeier C, Fruhmann G. Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency - three-year follow-up. Respiration 1997;64:10-5.
50. 1-antitrypsin deficiency? Eur Respir J 1997;10:2260-63.
51. 1-antitrypsin deficiency in emphysema. Chest 1996;110:284S-94S.
52. Casavilla FA, Reyes J, Tzakis A, et al. Liver transplantation for neonatal hepatitis as compared to the other two leading indications for liver transplantation in children. Hepatology 1994;21:1035-39.
53. Crystal RG. Alpha-1-antitrypsin deficiency, emphysema and liver disease: Genetic basis and strategies for therapy. J Clin Invest 1990;95:1343-52.
54. Wilson JKM. Molecular medicine: Adenoviruses as gene-delivery vehicles. N Engl J Med 1996;335:1185-87.
55. 1-antitrypsin gene of human cells by targeted homologous recombination. Lab Invest 1994;70:676-83.
56. Castanotto D, Rossi JJ, Sarver N. Antisense catalytic RNAs as therapeutic agents. Adv Pharmacol 1994;25:289-317.
57. Rhim JA, Sandgen EP, Degen JL, Brinster RL. Replacement of disease mouse liver by hepatic cell transplantation. Science 1994; 263:1149-52.
58. Overturf K, Al-Dhalimy M, Tanguay R, et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet 1996;12:266-73.
59. Gaczynska M, Rock KL, Goldber AL. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 1993;365:264-7.
60. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994;79:13-21.
61. Groll M, Ditzel L, Lowe J, et al. Structure of 20S proteasome from yeast at 2.4A resolution. Nature 1997;386:463-71.
62. Hilt W, Wolf DH. Proteasomes: Destruction as a programme. Trends Biochem Sci 1996;21:96-102.
63. Tanaka K, Tsurumi C. The 26S proteasome: Subunits and functions. Mol Biol Rep 1997;24:3-11.
64. Bordallo J, Plemper RK, Finger A, Wolf DH. Der3p/Hrd1p is required for endoplasmic reticulum associated degradation of misfolded luminal and integral membrane proteins. Mol Biol Cell 1998;9:209-22.
65. Knop M, Finger A, Braun T, Hellmuth K, Wolf DH. Der1, a novel protein specifically required for endoplasmic reticulum degradation in yeast. EMBO J 1996;15:753-63.
66. 1-antichymotrypsin and chronic liver disease. Histopathohgy 1990;16:221-5.
67. Wetsel RA, Kulics J, Lokki M-L, Kiepiela P, Akama H, Johnson CAC, Densen P, et al. Type II human complement C2 deficiency. J Biol Chem 1996;271:5824-31.
68. Ault BH, Schmidt BZ, Fowler NL, et al. Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem 1997; 272:25168-75.
69. Callea F, deVos R, Togni R, Taranico R, Vanstapel MJ, Desmet VJ. Fibrinogen inclusions in liver cells: A new type of ground-glass hepatocyte. Immune light and electron microscopic characterization. Histopathology 1986;10:65-73.
70. Miura O, Aoki N. Impaired secretion of mutant α2-plasmin inhibitor (α2-PI-Nara) from COS-7 and HepG2 cells: Molecular and cellular basis for hereditary deficiency of α2-plasmin inhibitor. Blood 1990;75:1092-96.
71. Yamamoto K, Tamimoto M, Emi N, Matsushita T, Takamatsu J, Saito H. Impaired secretion of the elongated mutant of protein C (protein C-Nagoya). J Clin Invest 1992;90:2439-16.
72. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: Mutational analysis of a membrane protein. Annu Rev Gener 1990;24:133-77.
73. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990;63:827-34.
74. Sandhoff K, Conzelmann E, Neufeld EF, Kaback MM, Suzuki K. The Gm2 gangliosidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease. 6th ed. New York: McGraw-Hill 1989:1807-39.
75. Sharp D, Blinderman L, Combs KA, et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinemia. Nature 1993;365:65-9.
76. Vesa J, Hellsten E, Verkruyse LA, et al. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 1995;376:584-7.
77. Fransen JAM, Hauri H-P, Ginsel LA, Naim HY. Naturally occurring mutations in intestinal sucrase-isomaltase provide evidence for the existence of an intracellular sorting signal in the isomaltase subunit. J Cell Biol 1991;115:45-57.
78. Kim PS, Swon O-Y, Arvan P. An endoplasmic reticulum storage disease causing congenital goiter with hypothyroidism. J Cell Biol 1996;133:517-27.
79. Prockop DJ, Chu M-L, DeWet W, et al. Mutations in osteogenesis imperfecta leading to the synthesis of abnormal type I procollagens. Ann NY Acad Sci 1985;460:289-97.
80. Schmale H, Bahnsen U, Richter D. Structure and expression of the vasopressin precursor gene in central diabetes insipidus. Ann NY Acad Sci 1993;689:74-82.
81. Cow A, Southwood CM, Lazzarini RA. Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease. J Cell Biol 1998;140: 925-34.